CanSino Biologics Inc (CJH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CanSino Biologics Inc (CJH) has a cash flow conversion efficiency ratio of -0.066x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-392.00 Million ≈ $-458.29 Million USD) by net assets (€5.97 Billion ≈ $6.98 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CJH equity financing ratio to measure how much of total assets are equity-financed.
CanSino Biologics Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how CanSino Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CJH operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
CanSino Biologics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CanSino Biologics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wuxi Hodgen Technology Co Ltd
SHE:300279
|
-0.006x |
|
BENZ MINING CORP CDI/1
F:1VU0
|
-0.404x |
|
Three Stars NM
SHG:603578
|
0.164x |
|
American Exceptionalism Acquisition Corp. A
NYSE:AEXA
|
0.000x |
|
Tera Light Ltd
TA:TRLT
|
0.028x |
|
China Railway Prefabricated Construction Co Ltd
SHE:300374
|
-0.015x |
|
Weihai Huadong Automation Co Ltd
SHE:002248
|
0.037x |
|
TrueLight
TWO:3234
|
-0.033x |
Annual Cash Flow Conversion Efficiency for CanSino Biologics Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of CanSino Biologics Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see CanSino Biologics Inc (CJH) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €4.95 Billion ≈ $5.79 Billion |
€77.86 Million ≈ $91.02 Million |
0.016x | +145.72% |
| 2024-12-31 | €4.91 Billion ≈ $5.74 Billion |
€-168.79 Million ≈ $-197.33 Million |
-0.034x | +80.16% |
| 2023-12-31 | €5.29 Billion ≈ $6.18 Billion |
€-916.25 Million ≈ $-1.07 Billion |
-0.173x | +32.19% |
| 2022-12-31 | €7.25 Billion ≈ $8.47 Billion |
€-1.85 Billion ≈ $-2.16 Billion |
-0.256x | -206.55% |
| 2021-12-31 | €8.55 Billion ≈ $9.99 Billion |
€2.05 Billion ≈ $2.40 Billion |
0.240x | +516.06% |
| 2020-12-31 | €6.07 Billion ≈ $7.10 Billion |
€-349.93 Million ≈ $-409.11 Million |
-0.058x | +45.05% |
| 2019-12-31 | €1.47 Billion ≈ $1.72 Billion |
€-154.25 Million ≈ $-180.33 Million |
-0.105x | +57.38% |
| 2018-12-31 | €502.32 Million ≈ $587.26 Million |
€-123.64 Million ≈ $-144.55 Million |
-0.246x | -165.51% |
| 2017-12-31 | €607.33 Million ≈ $710.03 Million |
€-56.30 Million ≈ $-65.82 Million |
-0.093x | +42.17% |
| 2016-12-31 | €214.47 Million ≈ $250.74 Million |
€-34.38 Million ≈ $-40.20 Million |
-0.160x | -- |
About CanSino Biologics Inc
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are i… Read more